Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Recruiting now · Phase 2

Conditions studied: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers

In brief

The goal of this clinical trial is to evaluate an investigational ultralow dose Positron Emission Tomography (PET) imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours

Key facts

Study ID
NCT07012993
Run by
Akiva Mintz
People needed
200
Starts
2025-05-20
Expected to finish
2030-06-30
Last updated by the study team
2026-04-13

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.